This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with great interest the article by Pasupathy et al1 reporting the beneficial role of the early administration of intravenous N-acetylcysteine with low-dose intravenous nitroglycerin in patients with acute ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention.
N-Acetylcysteine (NAC), by disrupting the disulfide bond in the von …
American Heart Association Professional?
Log in using your username and password
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
This Issue
Article Tools
Share this Article
- Letter by Mansour et al Regarding Article, “Early Use of N-Acetylcysteine With Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment–Elevation Myocardial Infarction Reduces Myocardial Infarct Size (the NACIAM Trial [N-Acetylcysteine in Acute Myocardial Infarction])”
